文章预览
Surging demand for weight loss drugs Wegovy and Zepbound from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) has fueled concerns over a significant risk linked to the popular drug class: loss of muscle mass . A growing list of biotechs is racing to address the issue. While the GLP-1s are good at causing weight loss, some of that weight reduction can come as loss of muscle mass. That can lead to additional concerns, such as injury risk, especially among the elderly, and a potential slowdown of metabolism, which can cause weight regain. Regeneron's (NASDAQ:REGN) chief scientific officer, George Yancopoulos, flagged the issue last week when he told The Financial Times that GLP-1s "could be leading to successive changes in body composition that could be creating more harm than good in the long term." The Eylea maker is among drug developers attempting to take on the problem by combining GLP-1s with other agents that can negate their effects on muscle tissue. Regeneron (REGN) is testing an ob
………………………………
